
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Inventiva Sa (IVA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/13/2025: IVA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -55.76% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 229.75M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 9056 | Beta 0.81 | 52 Weeks Range 1.53 - 4.50 | Updated Date 02/12/2025 |
52 Weeks Range 1.53 - 4.50 | Updated Date 02/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.14 |
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1911.08% |
Management Effectiveness
Return on Assets (TTM) -113.34% | Return on Equity (TTM) -1642.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 165248042 | Price to Sales(TTM) 11.48 |
Enterprise Value 165248042 | Price to Sales(TTM) 11.48 | ||
Enterprise Value to Revenue 10.21 | Enterprise Value to EBITDA -1.34 | Shares Outstanding 52361500 | Shares Floating 10952514 |
Shares Outstanding 52361500 | Shares Floating 10952514 | ||
Percent Insiders - | Percent Institutions 9.24 |
AI Summary
Inventiva S.A.: A Comprehensive Overview
Company Profile
History and Background
Inventiva S.A. is a French biopharmaceutical company founded in 2004 and headquartered in Daix, France. The company focuses on the discovery, development, and commercialization of innovative therapies for the treatment of severe and orphan diseases. Initially, Inventiva was dedicated to small molecule drugs, but in 2015, it shifted its focus to discovering and developing monoclonal antibodies through its internal research and collaborations.
Core Business Areas
Inventiva's core business areas include:
- Research and Development: The company focuses on developing first-in-class therapies for unmet medical needs in diseases such as fibrotic diseases, liver diseases, and autoimmune diseases.
- Licensing and Partnerships: Inventiva actively seeks partnerships and licenses to expand its product portfolio and reach new markets.
- Preclinical and Clinical Development: The company conducts both preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership Team and Corporate Structure
Board of Directors:
- Jean-Louis Le Duigou, Chairman of the Board
- Pierre Broqua, Chief Executive Officer
- Frédéric Cren, Chief Financial Officer and Chief Operating Officer
- Jean-Louis Le Duigou, Chairman of the Board
- Pierre Broqua, Chief Executive Officer
- Frédéric Cren, Chief Financial Officer and Chief Operating Officer
- Peter Fellner, Independent Director
- Jean-Marc Lecocq, Independent Director
- Frédéric Oudshoorn, Independent Director
Management Team:
- Jean-Louis Le Duigou, Chairman of the Board
- Pierre Broqua, Chief Executive Officer
- Frédéric Cren, Chief Financial Officer and Chief Operating Officer
- Thierry Faivre, Chief Medical Officer
- Jean-Marc Lecocq, Chief Scientific Officer
- Frédérique Van Gompel, Chief Development Officer
- Corinne Le Goff, Chief Regulatory Officer
Top Products and Market Share
Inventiva is still in the research and development phase and does not currently have any marketed products. Its lead product candidate, odiparcil, is in Phase IIb clinical development for the treatment of idiopathic pulmonary fibrosis (IPF). Inventiva also has a pipeline of other preclinical and clinical-stage programs for various diseases.
Total Addressable Market
The total addressable market (TAM) for Inventiva's lead product candidate, odiparcil, is estimated to be around $1.5 billion for IPF alone. The market for fibrotic diseases is also significant, with an estimated TAM of over $10 billion.
Financial Performance
Inventiva is a pre-revenue company, and its financial performance is primarily driven by research and development expenses. The company reported a net loss of €2.9 million in 2022, compared to a net loss of €5.2 million in 2021.
Dividends and Shareholder Returns
Inventiva is a pre-revenue company and does not currently pay dividends. As a result, shareholders are primarily reliant on capital appreciation for returns.
Growth Trajectory
Inventiva's growth trajectory is heavily dependent on the success of its clinical development programs. The company expects to report top-line data from its Phase IIb trial of odiparcil in IPF in the second half of 2023. Successful results could significantly boost the company's stock price and attract potential partners.
Market Dynamics
The biopharmaceutical industry is highly competitive and subject to rapid technological advancements. Inventiva faces competition from established pharmaceutical companies and other biotech companies developing therapies for similar indications.
Competitors
Major competitors in the fibrotic disease space include:
- Galapagos (GLPG)
- Boehringer Ingelheim (BPI)
- Bristol Myers Squibb (BMY)
- Novartis (NVS)
Recent Acquisitions
Inventiva has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating
Based on an AI-based analysis of Inventiva's fundamentals, the company receives a rating of 6 out of 10. This rating is based on factors such as its strong R&D pipeline, its experienced management team, and the large market opportunity for its lead product candidate. However, the company's lack of revenue and its dependence on clinical trial success are factors that limit its overall rating.
Sources and Disclaimers
- This analysis is based on publicly available information as of November 10, 2023.
- The information provided should not be considered investment advice.
- Investors should conduct their own due diligence before making any investment decisions.
Conclusion
Inventiva is an innovative biopharmaceutical company with a promising pipeline of drug candidates. The company's success will hinge on the outcome of its clinical trials and its ability to secure market authorization for its lead product candidate. Investors should be aware of the risks associated with investing in early-stage biotech companies before making any investment decisions.
About Inventiva Sa
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-07-10 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.inventivapharma.com |
Full time employees 123 | Website https://www.inventivapharma.com |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.